PL EN


Preferences help
enabled [disable] Abstract
Number of results
2013 | 40 | 1 | 31-52
Article title

Rak pęcherza moczowego – epidemiologia, diagnostyka i leczenie w XXI wieku

Content
Title variants
EN
Urinary bladder cancer – epidemiology, diagnostics and treatment in XXIst century
Languages of publication
EN
Abstracts
EN
Urinary bladder cancer is one of the most common cancers occurring in those aged older, especially between 60 and 80 years of age. In Poland, it is the fourth (after lung, prostate, and colon cancers) on/in the incidence of cancer in men and thirteenth in women. Epidemiological indicators of bladder cancer in Poland are disturbing to other European countries, where a decrease is observed in both morbidity and mortality. In the years 1991-2006 in Poland a very dynamic increase in the incidence of bladder cancer (reaching 59%) was recorded. What's more, our country ranks second, after Spain, in Europe in terms of mortality from this cancer. In the coming years the number of cases and deaths from bladder cancer in Poland is expected to increase. This article discusses new information/data on the epidemiology, methods of diagnosis and treatment of patients with bladder cancer.
Discipline
Year
Volume
40
Issue
1
Pages
31-52
Physical description
References
  • Wojciechowska U, Didkowska J, Zatoński W. Nowotwory złośliwe w Polsce w 2010 roku. Centrum Onkologii Instytut im. M. Skłodowskiej-Curie. Krajowy Rejestr Nowotworów, Warszawa, 2012: 51-113.
  • Borówka A. Rak pęcherza moczowego w Polsce. Przegl Urol. 2011; 66: 6-9.
  • Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou J i wsp. Guidelines on non-muscle-invasive bladder cancer. Eur Urol. 2011; 59: 584-594.
  • Droller MJ. Epidemiology of bladder cancer. W: Textbook of bladder cancer, Lerner SP, Schoenberg M, Sternberg CN (red.), Taylor and Francis, Abingdon, 2006: 3-12.
  • Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection. A combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer. 1999; 86: 1818-1826.
  • Kitamura H, Tsukamoto T. Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol. 2006; 11: 28-37.
  • Ozono S, Hinotsu S, Tabata S, Takashima K, Fujimoto K, Okajima E i wsp., Group NU-OR. Treated natural history of superficial bladder cancer. Jpn J Clin Oncol. 2001; 31: 536-540.
  • Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer. Epidemiology, diagnosis and management. Cancer Practice. 2002; 10: 311-322.
  • Schleicher L, Cordon-Cardo C, Petrylak DP. Rak pęcherza moczowego. W: Atlas chorób nowotworowych, Tom 2. Markman M (ed), Via Medica, Gdańsk, 2009: 178-182.
  • Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009; 3: 193 198.
  • Reuter VE. The pathology of bladder cancer. Urology. 2006; 67: 11-17.
  • Gouda I, Mokhtar N, Bilal D, El-Bolkainy T, El-Bolkainy NM. Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Natl Canc Inst. 2007; 19: 158-162.
  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
  • Babjuk M, Oosterlinck W, Sylvester RJ, Kaasinen E, Bohle A, Palou J, Roupret M. Guidelines on TaT1 (Non-muscle invasive) bladder cancer. EAU Guidelines, edition presented at the 25th EAU Annual Congress, Barcelona 2010. European Association of Urology. 2010.
  • Sobin LH, Gospodariwicz M, Wittekind C. TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. Wiley-Blackwell, 2009.
  • Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ i wsp. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011; 59: 1009-1018.
  • Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998; 22: 1435-1448.
  • Sauter G, Algaba F, Amin M, Busch C, Cheville J, Gasser T i wsp. Tumours of the urinary system: non-invasive urothelial neoplasias. W: WHO classification of tumors of the urinary system and male genital organs, Eble JN, Sauter G, Epstein Jl, Sesterhenn I (red.), IARCC Press, Lyon, 2004: 29-34.
  • Delclos GL, Lerner SP. Occupational risk factors. Scand J Urol Nephrol. 2008; Suppl: 58-63.
  • Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP. A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol. 2008; Suppl: 64-78.
  • Aveyard P, Adab P, Cheng KK, Wallace DM, Hey K, Murphy MF. Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int. 2002; 90: 228-239.
  • Bjerregaard BK, Raaschou-Nielsen O, Sorensen M, Frederiksen K, Christensen J, Tjonneland A i wsp. Tobacco smoke and bladder cancer-in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2006; 119: 2412-2416.
  • Puente D, Hartge P, Greiser E, Cantor KP, King WD, Gonzalez CA i wsp. A pooled analysis of bladder cancer case-control studies evaluating smoking in men and women. Cancer Causes Control. 2006; 17: 71-79.
  • Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L i wsp. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005; 66: 4 34.
  • Zieliński J. Klinika nowotworów narządów układu moczowo-płciowego. W: Urologia kliniczna, Zieliński J, Leńko J (eds) PZWL, Warszawa, 1993: 382 500.
  • Lipiński M. Metody diagnostyczne stosowane w rozpoznawaniu raka pęcherza moczowego. Przegl Urol. 2008; 9: 64-72.
  • Reynard J, Brewster S, Biers S. Nowotwory urologiczne: histopatologia i biologia molekularna. W: Oksfordzki podręcznik urologii, Bar K (red.), Wydawnictwo Czelej, Lublin, 2011: 206-227.
  • Palou J, Rodriguez-Rubio F, Huguet J, Segarra J, Ribal MJ, Alcaraz A i wsp. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol. 2005; 174: 859-861.
  • Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP i wsp. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005; 66: 35-63.
  • Dumache R, Puiu M, David D, Popovici M, Kaycsa A, Negru S i wsp. The importance of clinical application of molecular biomarkers in bladder cancer detection. Maedica (Buchar). 2010; 5: 124-127.
  • Dumache R, David D, Kaycsa A, Minciu R, Negru S, Puiu M. Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer. Rev Med Chir Soc Med Nat Iasi. 2011; 115: 163 167.
  • Goodison S, Rosser CJ, Urquidi V. Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Rev Proteomics. 2009; 6: 507-514.
  • Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J i wsp. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol. 2011; 60: 484-492.
  • Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005; 96: 798-802.
  • Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M i wsp. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004; 171: 135-138.
  • Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA i wsp., Group EG-UTCC. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002; 41: 523-531.
  • Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003; 170: 433-437.
  • Lopez-Beltran A, Bassi P, Pavone-Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol. 2004; 45: 257-266.
  • Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L i wsp. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49: 466-475.
  • Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004; 171: 2186-2190.
  • Gazzaniga P, Gradilone A, de Berardinis E, Sciarra A, Cristini C, Naso G i wsp. A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer. BJU Int. 2009; 104: 184-188.
  • Ojea A, Nogueira JL, Solsona E, Flores N, Gomez JM, Molina JR i wsp., Group C. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol. 2007; 52: 1398-1406.
  • Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK i wsp. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002; 60: 62-67.
Document Type
paper
Publication order reference
YADDA identifier
bwmeta1.element.psjd-d2a7ed95-b68c-462d-bf2d-6d3b98728166
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.